Microcap & Penny StocksEXTI - only public co. developing liver device

Previous 10 Next 10 
To: T. Scott Brassfield who wrote (773)1/25/2000 1:19:00 AM
From: Shawn Donahue
   of 1063


Thanks for the level of detail in your opinion. It makes logical sense that we would expect the FDA to approve a later generation device of a device that has already been proven safe enough to proceed to Phase 11/111.

<<What I think is superior about EXTI's device is the recirculating circuit
consisting of anoxygenator and mixer,O2 sensor, Ph sensor and oxygenator, and
this is what our Patent Pending pertains to. I would hope this technology
could create an environment that keeps the cells healthier (EXTI literature
refers to this as "methods for providing the proper conditions for continuous metabolism of human blood toxins by hepatocytes"-- with "proper conditions" being two important words)and allows cells to be added in the needed amount (perhaps
cost savings would be possible).>>

I'm no doctor, but the way you explain the benefits of EXTI's design, gives me tangible reasons for continuing to invest in the future of their product(s)! Do you have any idea what will be discussed at the stockholder's meeting in February? Volume seems to be consistently high. I wonder how many are buys and in what quantities. Anyone out there have any reports to track this? Thanks in advance!

Thanks Again,

PS: OUCH on those brand new Dynastars!I hope the ski areas get buried from the next storm :)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Shawn Donahue who wrote (778)1/26/2000 10:53:00 PM
From: Bob Lium
   of 1063
Shawn, We have been around a long time and .02 seemed like a long way off. Shawn do you understand just is happening? Has the stock been under priced,It seems we have a new base. It is my understanding all the stock has been sold and what we see is the float being traded. What are your thoughts and do you think we will see a forward split to increase the base of stock in time? Regards Bob Lium

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Bob Lium who wrote (779)1/28/2000 6:42:00 PM
From: Shawn Donahue
   of 1063


You are not kidding that we have been around a long time in EXTI, alot longer than when this board was started ! :) Even though the potential of the SybiolR technology and the growing and urgent need (and market)for a life saving liver dialysis machine, has not seemed to be a major question; financing seems to have been the biggest roadblock to getting through to FDA approval...The last two press releases woke me up to the possibility and hopefully reality of this stock and more importantly the chances of the sybiolR Liver Dialysis machine getting to market! I am most impressed by some of the favorable posts that I have read on the EXTI boards on Silicon Investor and RagingBull that seem to be from medical people who seem to understand and believe that EXTI may have the best technolgy. Alot of the EXTI investors seem to care as much about how this technology may save lives, as their investment paying off; and that keeps me LONG! I think that those kind of investors have caused the very high volume and have helped support this more respectible price! I am looking forward to after the stockholder's meeting and believe the fun may really begin as this technology hopefully proves itself to the FDA and moves through Phase 1 and starts to get the attention of maybe a larger partner. Who knows? You are right that .02 seems like a long way off, and I will not count on seeing that again!

As far as your question on a forward split is concerned,
why not? When I compared the outstanding shares of EXTI to BICO(who is developing a non-invasive glucose machine for diabetics), I found out that BICO has about 900 Million
and I read where they want to increase that to 1,700 Million (or 1.7 Billion!), so EXTI's 50 Million is no problem to me if they increase their outstanding shares ;)! The only type of split that I have a problem with is: Reverse. Why don't you call up Barbara or Jerry and see what they think? I certainly was glad to talk with them, when I called them up about those Hemocleanse posts and found out that they of course knew about the competition and company's that probably are not. :)


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Shawn Donahue who wrote (780)1/28/2000 7:15:00 PM
From: MaxLeverage
   of 1063
Here's a couple of sites that provide more info about SANGMA N. BRATIA, M.D.. Ph.D. She was the physician who's letter recommending Exten Industries was posted by T. Scott Brassfield last month:
Message 12384577

December 1, 1999


Assistant Professor of Bioengineering and Assistant Adjunct
Professor of Medicine, UCSD


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Danny Kim who wrote (750)2/4/2000 2:48:00 AM
From: Shawn Donahue
   of 1063


It certainly looks like Biotech stocks are again the place to be invested; especially ones from San Diego, according to the following article: I think EXTI should do everything it can to be part of this month's San Diego Biomedical Conference, What do you think? Look at how much some of the stock prices of these other companies have risen. GO EXTI! Shawn

While technology stocks soared stunningly last year, something extraordinary was happening under the radar: Biotechnology quietly returned to favor with silicon-weary investors. Biotech initial public offerings meet eager acceptance and stock values are rising in already public companies.
The biotech resurgence has hit San Diego full force, with many once-languishing stocks surging.
From January 1999 to last month, Nanogen has risen from less than $5 per share
to more than $30 per share; Corvas and Alliance Pharmaceuticals both climbed from about $3 per share to more than $9. Top rebound honors go to Amylin Pharmaceuticals
Inc., whose stock rose from less than 70 cents to nearly $12 per share.
There have been a few setbacks, too, such as a clinical trial failure in December for Isis Pharmaceuticals that caused its stock to lose 65 percent of its value in one day. But these disappointments didn't cause a general sell-off in the sector, as they might have a few years ago. Instead, investors rallied around stocks such as Maxim Pharmaceuticals, which skyrocketed from under $8 per share in September to nearly $40 by late January. The catalyst was continued good news for its anti-cancer drug Maxamine, which may rewrite the books on immunology if it successfully completes clinical trials this year. Meanwhile, Isis is preparing other shots at the brass ring with its "antisense" technology and can't be counted out.
Paradoxically, biotech success presents a new set of problems for San Diego -- the problems of how to provide big-city infrastructure in what in some ways is still a small town at heart. In the near term, San Diego's biotech outlook is strongly positive, like that of the rest of the country, industry leaders say.

ÿÿÿÿBacked by this comforting trend of resurgence,nine San Diego biotech and biomedical companies will present their stories this month at the San Diego Biomedical Conference hosted by local stock guru Bud Leedom. The companies: Alliance Pharmaceutical, Biosite Diagnostics, Collateral Therapeutics, Corvas International, Idec Pharmaceuticals, Isis Pharmaceuticals, Quidel Corp., Synbiotics Corp and Women First Healthcare Inc. Local
biotech veterans say part of the rebound comes from investors looking for new opportunities in an undervalued sector. But biotech companies also have made real progress in meeting their goals, says William H. Rastetter, Idec's president, chairman and CEO.
"The biotech industry is stronger today than it was two years ago. It was stronger two years ago than it was five years ago, and it was stronger five years ago than it was 10 years ago," Rastetter says. Companies have a far sturdier scientific base on which to research new products, and the U.S. Food and Drug Administration has become more of a partner and less of an adversary in getting new drugs to the market.

ÿÿÿÿIdec is the top star in San Diego's biotech firmament: It developed the blockbuster drug Rituxan for non-Hodgkin's lymphoma ($72 million in sales for the last quarter of 1999). Idec is now preparing to introduce an even more potent treatment for the disease, Zevalin. With a stock that topped $120 per share in early January, Idec's total market capitalization -- the total value of all its stock -- has exceeded $5 billion.

ÿÿÿÿIf anyone should be optimistic about San Diego biotech, it should be Rastetter, long active in promoting the local industry. However, Rastetter says he is growing more worried
about San Diego's viability as a biotech stronghold. The area's inability to provide the infrastructure biotechs need once they reach the manufacturing phase could lead them to
expand elsewhere.

ÿÿÿÿWhile biotechs were struggling to keep drug development going, that was not an issue, but with success the need to look to the future becomes more pressing. Rastetter cites the huge success of North Carolina's Research Triangle Park as an example of how good planning and infrastructure can nurture a huge biomedical and high-tech cluster. San Diego
has not had this planning. He warns that the area's traditional strategy of relying on the scientific prowess of UCSD, Scripps and Salk won't be enough. Once product
development moves out of the research stage other necessities come to the fore.

ÿÿÿÿ"We need a guaranteed supply of water, brine lines, other utilities and space to expand. Our plants have to be designed with overcapacity from the day they open (to allow for expansion)," Rastetter says. A high technology park with those amenities has been proposed for San Diego. However, a feasibility study needs to be done first, and no agency has volunteered to pay the $150,000 needed. Affordable land is available in the South County area; some have also suggested Temecula. But in biotech-speak, the idea hasn't gotten out of R & D and into the clinic.

ÿÿÿÿ"The problem is a lack of will," Rastetter says, and a lack of vision, too, to see how San Diego might look 20 or 30 years down the road, and the patience and tenacity to build toward that vision. That's not to say everyone lacks the will or vision, Rastetter adds. At the San Diego Regional Economic Development Corp, Julie Meier Wright is trying to find funding for the study.
ÿThe Comeback Kids
ÿÿÿÿMerely listing the jump in local biotech stock prices makes it seem effortless, a simple decision by investors to find new opportunities. But the biotech companies say the real story is one of steady, incremental progress in advancing their core technologies and exploring new market opportunities. At some point, the financial community gets a whiff of the change and starts to give a once-ignored company a more serious look. That's the story with Corvas International. There has never been any doubt that the company's research into cardiovascular products is focused on large markets with potentially big returns. Its scientists got headlines for their creativity in discovering an anticoagulant in blood-feeding hookworms, theorizing the compound could be transformed into a drug. However, over the years Corvas became stereotyped as a "research boutique" that could never quite focus on development and commercialization, says Randall E. Woods, Corvas
president and CEO.
Woods changed that, focusing attention on developing Corvas' oral and injectable anticoagulants, but also by bringing in a very respected investor, Stefan Engelhorn, one of the former owners of the German pharmaceutical giant, Boehringer Mannheim, now part of The Roche Group. Engelhorn joined three other investors in plunking down $15 million.
That's not a large amount of money as investments go, Woods concedes, but the presence of Engelhorn, and the favorable terms of the investment for Corvas gave other investors
confidence in the company.

ÿÿÿÿAlso, in December Corvas got an unexpected bonus: corporate partner Schering-Plough Corp. agreed to renew its longstanding collaboration to develop oral anticoagulants, giving Corvas $3 million to fund the work until December 2000. In December 1998, Corvas started a Phase II clinical trial of an injectable anticoagulant to prevent deep vein thrombosis. The anticoagulant is a recombinant protein called rNAPc2 that is the analog of the anticoagulant found in the hookworm.
ÿMeanwhile another corporate partner, Pfizer, is conducting a Phase II trial of a drug Corvas researched to treat ischemic stroke.
ÿCorvas has leveraged its cardiovascular expertise into the anticancer field. An enzyme similar to one that works in the blood "coagulation cascade" has been found to play a role
in the spread of cancer, called metastasis. Corvas is working on an inhibitor of this enzyme, called Urokinase Plasminogen activator.

ÿÿÿÿAlliance Pharmaceutical has been on the biotech
roller coaster for years, with its stock price rising and
falling while the company kept to a steady strategy of
developing from the same technological base a family of
oxygen-carrying products for cardiovascular and pulmonary uses; and developing imaging contrast agents.

ÿÿÿÿTed Roth, Alliance's president and chief operating
officer, says the progress at Alliance and many other
biomedical companies had been "virtually ignored for
the last year or two," until the fall of 1999. "Nobody
seemed to care."

ÿÿÿÿOne factor hurting Alliance was a legal dispute with
its former partner, Hoechst Marion Roussel Inc. That spat was settled in September, and the stock began rising from under $4 per share to more than $9 a share in January. On Dec. 1, Alliance reported progress in a Phase III trial of its Oxygent temporary blood substitute and on Dec. 14, Alliance reported that the FDA had accepted for review its New Drug Application to approve Imagent, its ultrasound contrast agent.
As a private company, Applied Molecular Evolution doesn't have to worry about a stock price -- yet. The biotech formerly known as Ixsys is concerned about advancing and
protecting technology it has licensed in the hot field of directed evolution.

ÿÿÿÿTaking its cue from Charles Darwin's great discovery of evolution through natural selection, Applied Molecular Evolution uses mutation and artificial selection to mold what appears in nature into forms that fit human needs. The process quickly creates randomly varying types of a specific protein, selects the variants that most closely match a
pre-determined function, then cycles the second-generation products back through the loop. The end result is a protein-based drug that can be more than a hundred times as
potent, stripped of unwanted side effects. For example, an antibody derived from an animal can be "humanized" so it won't be neutralized by the human immune system.
Molecular evolution is the opposite of earlier attempts to precisely engineer a drug to a molecular target by understanding its structure down to the atomic level. Molecular Darwinism doesn't require that degree of precision: chance, guided by a human hand, comes up with the answer. Applied Molecular has worked for years improving target molecules for Bristol-Myers Squibb as the pharmaceutical company researches new drugs for cancer, and more recently in a February 1999 deal with MedImmune to develop monoclonal antibodies. But much more is possible with the technology, says Larry Bloch, Applied Molecular's vice president of business development.
ÿÿ"Our technology platform is so powerful that we can take an existing marketed and approved therapeutic and come out with a more potent therapeutic," Bloch says. The result
is a new drug that qualifies for another patent, serving the needs of patients for a better drug as well as the company's financial interests by forestalling generic competition. That's the goal of the company's new Phase IV division. The company is also looking to expand into industrial processes by producing enzymes used in manufacturing.

ÿÿÿÿThe company got its technology in 1995 through an exclusive worldwide license of the discovery by two scientists, Marc Ballivet and Stuart Kauffman. The patent embodies broad claims for methods of generating "libraries" of DNA, RNA, protein and peptide molecules, and how to identify molecules that are linked with specific biological activities.
ÿHowever, a Redwood City company, Maxygen, went public last year on the strength of its own directed evolution technology. When asked how that was possible, Bloch replied,
"That's a good question." Applied Molecular's attorneys are now researching that question, Block adds. Hmmm. Patent wars. That's a sure sign of an industry with a lot of value to protect.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: MaxLeverage who wrote (781)2/4/2000 4:09:00 PM
From: Shawn Donahue
   of 1063

It appears that the money is out there for companies who want to provide solutions "to combat" Hepatitus-C. I forwarded this to EXTI and hopefully they will follow up.

PS: Richard, Thanks for the research on DR. Bratia; who gave the expert opinion that EXTI's SybiolR seemed to offer the best technology...

Philadelphia allocates millions to sick firefighters

PHILADELPHIA (Reuters) - The city of Philadelphia agreed Monday to allocate millions of dollars to combat a hepatitis-C epidemic that has infected 130 firefighters to date with the deadly disease.

In an issue watched closely by firefighters across the United States, Mayor John Street said the city would spend up to $3 million to cover treatment this year for as many as 200 firemen at a rate of $1,500 a month. The mayor said the city government would consider covering long-term treatment costs as well.

``We will make whatever adjustments are necessary. We think it is the right thing to do,' Street said. ``This is one of the most devastating problems that can happen to a family.'

Details of the plan were to be worked out with the city's 2,100-member firefighters union. The announcement was expected to remove the cost of hepatitis treatment from the bargaining table in upcoming labor talks aimed at replacing a union contract that expires June 30.

The agreement was seen as a victory for union officials who have lobbied for months on behalf of 130 firefighters that contracted the disease after being exposed to tainted blood during emergency rescues.

Hepatitis-C is a liver infection that can be transmitted through blood or intravenous drug use. First identified in 1989, the virus can lead to liver failure and cancer.

About four million people in the United States have hepatitis-C, which kills 10,000 Americans a year. But those infected may not show symptoms for 10 to 20 years.

Experts said the city's experience should come as a warning to U.S. firefighters in general, who are often exposed to the blood of fire and accident victims.

``I'm sure this is the tip of the iceberg,' Martin Black, head of the liver unit at Temple University, told the Philadelphia Inquirer. ``Firefighters use blood smeared over them as a badge of honor.'

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Shawn Donahue who wrote (783)2/8/2000 2:13:00 AM
From: CENTrader
   of 1063
Message 12805324

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: CENTrader who wrote (784)2/8/2000 4:52:00 PM
From: Shawn Donahue
   of 1063
Bill (ComVest),

Thanks for the link! I see that this Dr. used to work for the FDA...maybe he or someone else can help EXTI to get FastTrack approval!

Are you or Rich attending the EXTI stockholder's meeting on the 25th of this month? (I went over to the RagingBull EXTI board to read the announcement again, because for some reason the "In the News" section of Exten's website comes up blank...anyone else notice this? Did they not code the website to be Netscape compliant?)

Did you get a chance to read that article about how other San Diego biotech company's stock prices are going through the roof this year? There seems to be plenty of interest and money available for biotech company's...let's hope that EXTI knows how to keep getting the word out on what they intend to accomplish...GO EXTI!


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: Shawn Donahue who wrote (785)2/8/2000 11:24:00 PM
From: CENTrader
   of 1063

I would like to think at some point the word "fast track" would appear in an EXTI press release or on the website. Fast Track Approval is "made to order" for this stock! (for godddsssakes!)

Yes, I read that article on biotechs & share price. EXTI seems to be responding finally....and we're lookin' good. I think we're in for some exciting times ahead. $10/share is my magic number...then I can live happily ever after!

Good to see your still around and keeping the faith.

Best Regards,


Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: CENTrader who wrote (786)2/15/2000 2:57:00 AM
From: Shawn Donahue
   of 1063


I saw your message about the EXTI stockholder's meeting being delayed for auditing to be finished...and so I wrote to Barbara and Jerry for clarification. It looks like they are doing the right thing and that things are moving nicely forward! Here is the email that I received below:

PS: Your $10 "magic number" would suit me fine too! :)Of course that is secondary to getting the potentially life saving Sybiolr to market!

Subj: Re: EXTI Stockholder's Meeting posting
Date: 00-02-14 14:10:33 EST

Dear Shawn,
Here is the text; Jerry has reviewed and corrected my typo. It is OK to post all or part if you wish:
The meeting is not on the 25th. The reason given (auditing) IS indeed the reason the meeting was postponed. Companies must send the annual report with the proxy material. The annual report must be verified by independent auditors. We have a new auditing firm. They did not conduct the audit fast enough to make the original target date. As I tell everyone who asks, the proxy material and 10 K and meeting information including the new date will be mailed by an independent firm to all shareholders soon. We are deciding a realistic timetable to do all the printing and SEC notification work and vote tabulation etc. as soon as possible, and we hope to be able to tell you the meeting date soon. Your letter was obviously written with the best interests of the company in mind, and I do thank you, and we will do the best we can to get the meeting process firmed up ASAP.

Barbara L. Corbett

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10 

Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.